Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 26-50 of 138

  • Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced / Metastatic Solid Tumors

    This study is an open-label Phase 1 / Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced / metastatic solid tumors.
    Location: 8 locations

  • A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

    The purpose of this study is to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
    Location: 9 locations

  • A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

    The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advanced gastrointestinal and genitourinary tumors.
    Location: 9 locations

  • Nivolumab and Cabozantinib S-malate in Treating Patients with Advanced or Metastatic Kidney Cancer

    This phase II trial studies how well nivolumab and cabozantinib s-malate work in treating patients with kidney cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and cabozantinib s-malate may work better in treating patients with advanced or metastatic kidney cancer.
    Location: 7 locations

  • Axitinib with or without Anti-OX40 Antibody PF-04518600 in Treating Patients with Metastatic Kidney Cancer

    This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from living organisms that may stimulate the immune system in different ways and stop tumor cells from growing. Giving axitinib with or without anti-OX40 antibody PF-04518600 may work better in treating patients with kidney cancer.
    Location: 9 locations

  • Pazopanib Hydrochloride with or without Ascorbic Acid in Treating Patients with Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

    This randomized phase II trial studies how well pazopanib hydrochloride with or without ascorbic acid work in treating patients with kidney cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ascorbic acid may help pazopanib hydrochloride stop tumor growth and improve treatment survival. Giving pazopanib hydrochloride and ascorbic acid may work better in treating patients with kidney cancer.
    Location: 7 locations

  • A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors

    To better understand the safety and tolerability of ALKS 4230 in humans
    Location: 6 locations

  • Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

    The purpose of this first-in-human study of MBG453 is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v. as a single agent or in combination with PDR001 in adult patients with advanced solid tumors
    Location: 7 locations

  • Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

    This is a Phase 1b / 2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the PARP inhibitor talazoparib in participants with advanced / metastatic solid tumors.
    Location: 6 locations

  • A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

    This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD / RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.
    Location: 6 locations

  • QUILT-3.055: A Study of ALT-803 in Combination With PD-1 / PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer

    This is a Phase IIb, single-arm, multicohort, open-label multicenter study of ALT-803 in combination with an FDA-approved PD-1 / PD-L1 checkpoint inhibitor in patients with advanced cancers who have progressed following an initial response to treatment with PD-1 / PD-L1 checkpoint inhibitor therapy. All patients will receive the combination treatment of PD-1 / PD-L1 checkpoint inhibitor plus ALT-803 for up to 16 cycles. Each cycle is six weeks in duration. All patients will receive ALT-803 once every 3 weeks. Patients will also receive the same checkpoint inhibitor that they received during their previous therapy. Radiologic evaluation will occur at the end of each treatment cycle. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the Investigator feels it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months past administration of the first dose of study drug.
    Location: 5 locations

  • A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

    The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR.
    Location: 5 locations

  • A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma

    The purpose of this study is to determine whether the combination of nivolumab and ipilimumab is safe and effective for delaying or preventing recurrence of cancer in patients who have experienced the partial or entire removal of a kidney
    Location: 5 locations

  • Study CB-839 in Combination With Nivolumab in Patients With Melanoma, ccRCC and NSCLC

    This study is an open-label Phase 1 / 2 evaluation of CB-839 in combination with nivolumab in patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
    Location: 8 locations

  • A Phase 1 / 2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

    This is an open-label, multicenter Phase 1 / 2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator polyICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.
    Location: 6 locations

  • Pazopanib Hydrochloride and Bevacizumab in Treating Patients with Previously Untreated Metastatic Kidney Cancer

    This phase I / II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can prevent tumor growth by blocking the ability of tumor cells to grow and spread. Giving pazopanib hydrochloride together with bevacizumab may kill more tumor cells.
    Location: 5 locations

  • A Study of XmAb®22841 Monotherapy & in Combination w / Pembrolizumab in Subjects w / Selected Advanced Solid Tumors

    This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and / or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.
    Location: 5 locations

  • TRQ15-01 in Patients With Relapsed / Refractory Solid Tumors and Lymphomas

    The purpose of this study is to assess the safety and tolerability of escalating doses of TRQ15-01 in patients with relapsed / refractory / metastatic or locally-advanced solid tumors and lymphomas.
    Location: 5 locations

  • GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

    The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed / refractory (R / R) Head and Neck Squamous Cell Carcinomas (HNSCC) to warrant further clinical investigation (Part 2). Part 1 (dose escalation) will enroll subjects with advanced, selected solid tumors. Subjects will receive escalating doses of GSK3359609 and tremelimumab in combination in Part 1. Part 2 is randomized expansion and will enroll subjects with R / R HNSCC who have disease progression after receiving at least 1 platinum-based chemotherapy and at least 1 anti-programmed death receptor protein-1 (PD-1) / anti-programmed death-ligand 1 (PD-L1) therapy, whether in combination or separately. In Part 2, subjects will be randomized in a ratio of 2:1 to receive either GSK3359609 in combination with tremelimumab at the recommended Phase 2 dose or investigators choice of a single-agent standard of care (SOC) therapy including paclitaxel, docetaxel or cetuximab. The total duration of subjects in the study will be approximately 4 years.
    Location: 4 locations

  • Pembrolizumab and Cabozantinib S-malate in Treating Patients with Locally Advanced, Recurrent, or Metastatic Kidney Cancer

    This phase I / II trial studies how well cabozantinib s-malate works when given together with pembrolizumab in treating patients with kidney cancer that has come back, spread from where it started to nearby tissue or lymph nodes, or spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and cabozantinib s-malate may work better in treating patients with renal cell carcinoma.
    Location: 4 locations

  • A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

    This is a Phase 1, open-label, multicenter study of continuous oral dosing of AZD4635 administered to patients with advanced solid malignancies. Dosing will be escalated until a maximum-tolerated dose (MTD) is determined in patients. The MTD will be defined by dose-limiting toxicity. Other dosing schedules may be evaluated based on the emerging PK and safety data. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of the patients. The primary objectives of this study are to: - Investigate the safety and tolerability of AZD4635 monotherapy when given orally (PO) to patients with advanced solid malignancies. - Investigate the safety, tolerability, and pharmacokinetics (PK) of AZD4635 monotherapy capsule formulation when given to patients with advanced solid malignancies. - Investigate the safety and tolerability of AZD4635 PO when given in combination with durvalumab, durvalumab plus oleclumab, or docetaxel to patients with advanced solid malignancies and to investigate the safety and tolerability of AZD4635 in combination with abiraterone acetate or enzalutamide in patients with mCRPC. - Define the maximum-tolerated dose (MTD) of AZD4635 in combination with durvalumab. - Define the recommended Phase 2 dose (RP2D) of AZD4635 in combination with abiraterone acetate or enzalutamide. - Determine the safety, tolerability, and immune effects of AZD4635 when administered in combination with durvalumab to patients with non-small cell lung cancer (NSCLC) who have previously received immunotherapy (Phase 1b portion). - Investigate the safety and tolerability of AZD4635 capsule formulation in combination with durvalumab and oleclumab when given to patients with mCRPC or advanced solid tumor malignancy. - Define the RP2D of AZD4635 capsule formulation in combination with durvalumab and oleclumab when given to patients with mCRPC or advanced solid tumor malignancy. - Investigate the safety and tolerability of AZD4635 capsule formulation in combination with docetaxel when given to patients with mCRPC or advanced solid tumor malignancy. - Define the RP2D of AZD4635 capsule formulation in combination with docetaxel when given to patients with mCRPC or advanced solid tumor malignancy.
    Location: 4 locations

  • An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors

    The purpose of this study is to determine if BMS-986310 administered in combination with nivolumab, will demonstrate adequate safety and tolerability, as well as a favorable risk / benefit profile, to support further clinical testing.
    Location: 3 locations

  • Cabozantinib or Sunitinib Malate in Treating Participants with Metastatic Variant Histology Renal Cell Carcinoma

    This phase II trial studies of side effects of cabozantinib and sunitinib malate and to see how well they work in treating participants with variant histology kidney cancer that has spread to other places in the body. Cabozantinib and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • High Dose Aldesleukin with or without Entinostat in Treating Patients with Metastatic or Unresectable Renal Cell Cancer

    This phase II trial studies how well high dose aldesleukin with or without entinostat work in treating patients with renal cell cancer that has spread to other areas of the body (metastatic) or cannot be removed by surgery (unresectable). Interleukins are proteins made by white blood cells and other cells in the body that may help regulate immune response. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if high dose aldesleukin with or without entinostat may work better in treating patients with renal cell cancer.
    Location: 6 locations

  • A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

    This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or in combination with CDX-301, and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
    Location: 4 locations